Not a diet. A new biology.

No. Compounded semaglutide is not FDA-approved as a finished drug product. The FDA does not evaluate compounded medications for safety, effectiveness, or quality the way it does brand-name drugs. It is legally prepared by a licensed 503A compounding pharmacy and prescribed by a licensed provider. If safety is your primary concern, FDA-approved Wegovy® or Ozempic® are the more conservative options.

Ozempic® and Wegovy® contain FDA-approved semaglutide manufactured by Novo Nordisk. Compounded semaglutide contains the same active ingredient but is prepared by a compounding pharmacy — not manufactured by the original drug maker and not FDA-approved as a finished product. Brand-name versions cost $900–$1,400/month without insurance. Rylo’s compounded version starts at $129/month. Both require a prescription from a licensed provider.

Individual results vary significantly. Published clinical trial data for semaglutide shows an average of 14% body weight loss over 68 weeks alongside diet and exercise. Some patients notice reduced appetite within the first 1–2 weeks. These results are from FDA-approved semaglutide trials — compounded versions have not been independently studied. Results are not guaranteed.

The most common side effects are GI-related — nausea, diarrhea, constipation, or vomiting — especially during the first weeks of treatment. These typically ease as your body adjusts. Serious but rare risks include pancreatitis, gallbladder problems, and a potential increased risk of thyroid tumors. Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN2. Your provider will review your complete health history before prescribing.

Yes. No contracts and no cancellation fees. Cancel anytime through your patient portal or by messaging our support team. Your current month’s shipment will always be sent before any cancellation takes effect.